<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192308</url>
  </required_header>
  <id_info>
    <org_study_id>KINETAM</org_study_id>
    <nct_id>NCT01192308</nct_id>
  </id_info>
  <brief_title>PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)</brief_title>
  <acronym>KINETAM</acronym>
  <official_title>PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All women on tamoxifen receive the standard dose of 20mg QD, irrespective of the use of&#xD;
      potential CYP2D6 inhibitors, and are not tested for CYP2D6 polymorphisms prior to start of&#xD;
      tamoxifen treatment.However CYP2D6 polymorphisms and/or the use of CYP2D6 inhibitors as&#xD;
      co-medication may influence the treatment outcome of tamoxifen.&#xD;
&#xD;
      The investigators propose a prospective study in women taking tamoxifen at a dose of 20mg QD.&#xD;
      In each woman, information will be collected on endoxifen levels, CYP2D6 status, adherence&#xD;
      and use of co-medication. In women who are phenotypically poor metabolizers of tamoxifen, a&#xD;
      dose increase to 40mg QD will be applied and the effect of this intervention on tamoxifen&#xD;
      pharmacokinetics will be evaluated after 4 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although already some information is available on the importance of CYP2D6 polymorphisms&#xD;
      and/or the use of CYP2D6 inhibitors as co-medication that may influence the treatment outcome&#xD;
      of tamoxifen, this information does currently not lead to a change in the management of this&#xD;
      patient population. All women on tamoxifen receive the standard dose of 20mg QD, irrespective&#xD;
      of the use of potential CYP2D6 inhibitors, and are not tested for CYP2D6 polymorphisms prior&#xD;
      to start of tamoxifen treatment.&#xD;
&#xD;
      In an attempt to at least resolve some of these issues we propose a prospective study in&#xD;
      women taking tamoxifen at a dose of 20mg QD who are being followed at several large oncology&#xD;
      clinics in the south-eastern part of the Netherlands (Nijmegen (CWZ &amp; Radboud), Den Bosch,&#xD;
      Harderwijk and Arnhem). In each woman, information will be collected on endoxifen levels,&#xD;
      CYP2D6 status, adherence and use of co-medication. In women who are phenotypically poor&#xD;
      metabolizers of tamoxifen, a dose increase to 40mg QD will be applied and the effect of this&#xD;
      intervention on tamoxifen pharmacokinetics will be evaluated after 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tamoxifen and metabolites plasmaconcentration</measure>
    <time_frame>week 0 and 4</time_frame>
    <description>Trough samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>week 0 and 4</time_frame>
    <description>Collection of adverse events during entire trial.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>40mg QD dose intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg QD dose intervention during 4 weeks in patients with CYP2D6 variant allele or using CYP2D6 inhibitor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen 40mg QD</intervention_name>
    <description>Tamoxifen 40mg QD during 4 weeks</description>
    <arm_group_label>40mg QD dose intervention</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is at least 18 years at screening.&#xD;
&#xD;
          -  Subject is able and willing to sign the Informed Consent Form prior to screening&#xD;
             evaluations.&#xD;
&#xD;
          -  Subject is a female patient with (a history of) breast cancer and has been treated&#xD;
             with tamoxifen 20mg QD for at least 4 weeks and is expected to be treated for at least&#xD;
             another 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to understand the nature and extent of the trial and the procedures&#xD;
             required.&#xD;
&#xD;
          -  Participation in a drug trial within 60 days prior to the first dose.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Burger, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Welzen ME, Dezentj√© VO, van Schaik RH, Colbers AP, Guchelaar HJ, van Erp NP, den Hartigh J, Burger DM, van Laarhoven HW. The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity. Ther Drug Monit. 2015 Aug;37(4):501-7. doi: 10.1097/FTD.0000000000000195.</citation>
    <PMID>26192892</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>CYP2D6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

